Contineum Therapeutics (CTNM) Enterprise Value (2024 - 2026)

Contineum Therapeutics' Enterprise Value history runs 4 years deep, the most recent figure standing at -$236.6 million for Q2 2026.

• In Q2 2026, Enterprise Value fell 34.8% year-over-year to -$236.6 million; the TTM figure through Jun 2026 stood at -$236.6 million (down 34.8% YoY), while the FY2025 annual figure was -$262.9 million, down 28.39% from the prior year.
• Enterprise Value for Q2 2026 stood at -$236.6 million, up from -$246.3 million in the prior quarter.
• The five-year high for Enterprise Value was -$117.9 million in Q1 2024, with the low at -$262.9 million in Q4 2025.
• The 4-year median for Enterprise Value is -$204.8 million (2024), against an average of -$197.7 million.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value sank 63.56% in 2024, then grew 19.74% in 2025.
• Contineum Therapeutics' Enterprise Value stood at -$125.2 million in 2023, then tumbled by 63.56% to -$204.8 million in 2024, then decreased by 28.39% to -$262.9 million in 2025, then climbed by 10.02% to -$236.6 million in 2026.
• Business Quant data shows CTNM's Enterprise Value at -$236.6 million in Q2 2026, -$246.3 million in Q1 2026, and -$262.9 million in Q4 2025.